Liposomal amphotericin B: What is its role in 2008?

Clinical Microbiology and Infection

Volumn 14, Issue SUPPL. 4, 2008, Pages 71-83

  Lanternier, F ^a   Lortholary, Olivier ^a,b  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b INSTITUT PASTEUR   (France)

Author keywords

Liposomal amphotericin B; Review

Indexed keywords

AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CASPOFUNGIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MEGLUMINE ANTIMONATE; MICAFUNGIN; POSACONAZOLE; PYRROLE; VORICONAZOLE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBIOTIC RESISTANCE; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ASPERGILLOSIS; BLASTOMYCES; BLOOD TOXICITY; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDEMIA; CANDIDIASIS; CLINICAL TRIAL; COCCIDIOIDES; COMBINATION CHEMOTHERAPY; CRYPTOCOCCAL MENINGITIS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GEOTRICHUM; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HISTOPLASMA; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HYPOKALEMIA; INFECTION RISK; KIDNEY FAILURE; LEISHMANIASIS; MONOTHERAPY; MUCORMYCOSIS; MYCOSIS; NEPHROTOXICITY; NONHUMAN; PARACOCCIDIOIDES; PRIORITY JOURNAL; REVIEW; RHODOTORULA; RIGOR; SIDE EFFECT; TRICHOSPORON; UNSPECIFIED SIDE EFFECT;

AJELLOMYCES; ASPERGILLUS; BLASTOMYCES; CANDIDA; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; FUNGI; GEOTRICHUM; HUMAN IMMUNODEFICIENCY VIRUS; RHODOTORULA (ERYTHROBASIDIUM CLADE); TRICHOSPORON (UNCLASSIFIED);

EID: 42649107495     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2008.01984.x     Document Type: Review

References (68)

1. MA Pfaller DJ Diekema DL Gibbs Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing J Clin Microbiol 45 2007 1735 1745
2. WE Trick SK Fridkin JR Edwards RA Hajjeh RP Gaynes Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989–1999 Clin Infect Dis 35 2002 627 630
3. AM Tortorano J Peman H Bernhardt Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study Eur J Clin Microbiol Infect Dis 23 2004 317 322
4. RA Hajjeh AN Sofair LH Harrison Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program J Clin Microbiol 42 2004 1519 1527
5. MA Pfaller SA Messer RJ Hollis RN Jones DJ Diekema In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp Antimicrob Agents Chemother 46 2002 1723 1727
6. J Mora-Duarte R Betts C Rotstein Comparison of caspofungin and amphotericin B for invasive candidiasis N Engl J Med 347 2002 2020 2029
7. BJ Kullberg JD Sobel M Ruhnke Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial Lancet 366 2005 1435 1442
8. O Ringden F Meunier J Tollemar Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients J Antimicrob Chemother 28 suppl B 1991 73 82
9. A Scarcella MB Pasquariello B Giugliano M Vendemmia A de Lucia Liposomal amphotericin B treatment for neonatal fungal infections Pediatr Infect Dis J 17 1998 146 148
10. A Juster-Reicher E Leibovitz N Linder Liposomal amphotericin B (AmBisome) in the treatment of neonatal candidiasis in very low birth weight infants Infection 28 2000 223 226
11. N Linder G Klinger I Shalit Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations J Antimicrob Chemother 52 2003 663 667
12. ER Kuse P Chetchotisakd CA da Cunha Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial Lancet 369 2007 1519 1527
13. JR Wingard MH White E Anaissie J Raffalli J Goodman A Arrieta A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group Clin Infect Dis 31 2000 1155 1163
14. L Ostrosky-Zeichner KA Marr JH Rex SH Cohen Amphotericin B: time for a new ‘gold standard’ Clin Infect Dis 37 2003 415 425
15. PG Pappas JH Rex JD Sobel Guidelines for treatment of candidiasis Clin Infect Dis 38 2004 161 189
16. DW Denning CC Kibbler RA Barnes British Society for Medical Mycology proposed standards of care for patients with invasive fungal infections Lancet Infect Dis 3 2003 230 240
17. S Bretagne C Durand J Bille Conference de conscensus prise en charge des candidoses et des aspergilloses invasives 2004 Med Mal Infect 2004 Numéro special.
18. R Herbrecht DW Denning TF Patterson Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis N Engl J Med 347 2002 408 415
19. TF Patterson HW Boucher R Herbrecht Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome Clin Infect Dis 41 2005 1448 1452
20. AC Leenders S Daenen RL Jansen Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections Br J Haematol 103 1998 205 212
21. M Ellis D Spence B de Pauw An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis Clin Infect Dis 27 1998 1406 1412
22. TJ Walsh JL Goodman P Pappas Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study Antimicrob Agents Chemother 45 2001 3487 3496
23. OA Cornely J Maertens M Bresnik Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial) Clin Infect Dis 44 2007 1289 1297
24. C Cordonnier M Bresnik R Ebrahimi Liposomal amphotericin B (AmBisome) efficacy in confirmed invasive aspergillosis and other filamentous fungal infections in immunocompromised hosts: a pooled analysis Mycoses 50 2007 205 209
25. J Wheat G Sarosi D McKinsey Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America Clin Infect Dis 30 2000 688 695
26. O Lortholary DW Denning B Dupont Endemic mycoses: a treatment update J Antimicrob Chemother 43 1999 321 331
27. PC Johnson LJ Wheat GA Cloud Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS Ann Intern Med 137 2002 105 109
28. LJ Wheat G Cloud PC Johnson Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole Antimicrob Agents Chemother 45 2001 2354 2357
29. AE Brouwer A Rajanuwong W Chierakul Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial Lancet 363 2004 1764 1767
30. F Dromer S Mathoulin-Pelissier O Launay O Lortholary Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study PLoS Med 4 2007 e21
31. MS Saag RJ Graybill RA Larsen Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America Clin Infect Dis 30 2000 710 718
32. AC Leenders P Reiss P Portegies Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis AIDS 11 1997 1463 1471
33. E Dannaoui J Meletiadis JW Mouton JF Meis PE Verweij In vitro susceptibilities of zygomycetes to conventional and new antifungals J Antimicrob Chemother 51 2003 45 52
34. E Dannaoui JF Meis D Loebenberg PE Verweij Activity of posaconazole in treatment of experimental disseminated zygomycosis Antimicrob Agents Chemother 47 2003 3647 3650
35. RN Greenberg K Mullane JA van Burik Posaconazole as salvage therapy for zygomycosis Antimicrob Agents Chemother 50 2006 126 133
36. JA van Burik RS Hare HF Solomon ML Corrado DP Kontoyiannis Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases Clin Infect Dis 42 2006 e61 e65
37. HA Torres RY Hachem RF Chemaly DP Kontoyiannis II Raad Posaconazole: a broad-spectrum triazole antifungal Lancet Infect Dis 5 2005 775 785
38. R Herbrecht Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections Int J Clin Pract 58 2004 612 624
39. L Pagano M Offidani L Fianchi Mucormycosis in hematologic patients Haematologica 89 2004 207 214
40. A Nosari P Oreste M Montillo Mucormycosis in hematologic malignancies: an emerging fungal infection Haematologica 85 2000 1068 1071
41. TJ Walsh SJ Chanock Diagnosis of invasive fungal infections: advances in nonculture systems Curr Clin Top Infect Dis 18 1998 101 153
42. R Herbrecht V Letscher-Bru RA Bowden Treatment of 21 cases of invasive mucormycosis with amphotericin B colloidal dispersion Eur J Clin Microbiol Infect Dis 20 2001 460 466
43. M Bjorkholm G Runarsson F Celsing M Kalin B Petrini P Engervall Liposomal amphotericin B and surgery in the successful treatment of invasive pulmonary mucormycosis in a patient with acute T-lymphoblastic leukemia Scand J Infect Dis 33 2001 316 319
44. T Parkyn AW McNinch T Riordan M Mott Zygomycosis in relapsed acute leukaemia J Infect 41 2000 265 268
45. EORTC International Antimicrobial Therapy Cooperative Group Empiric antifungal therapy in febrile granulocytopenic patients Am J Med 86 1989 668 672
46. PA Pizzo KJ Robichaud FA Gill FG Witebsky Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia Am J Med 72 1982 101 111
47. J Maertens K Theunissen G Verhoef Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study Clin Infect Dis 41 2005 1242 1250
48. TJ Walsh RW Finberg C Arndt Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group N Engl J Med 340 1999 764 771
49. TJ Walsh P Pappas DJ Winston Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever N Engl J Med 346 2002 225 234
50. TJ Walsh H Teppler GR Donowitz Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia N Engl J Med 351 2004 1391 1402
51. C Girmenia ML Moleti A Micozzi Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation J Clin Microbiol 43 2005 5395 5396
52. D Goodman E Pamer A Jakubowski C Morris K Sepkowitz Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate Clin Infect Dis 35 2002 E35 E36
53. A Safdar EB Papadopoulos JW Young Breakthrough Scedosporium apiospermum (Pseudallescheria boydii) brain abscess during therapy for invasive pulmonary aspergillosis following high-risk allogeneic hematopoietic stem cell transplantation. Scedosporiasis and recent advances in antifungal therapy Transpl Infect Dis 4 2002 212 217
54. D Wagner A Sander H Bertz J Finke WV Kern Breakthrough invasive infection due to Debaryomyces hansenii (teleomorph Candida famata ) and Scopulariopsis brevicaulis in a stem cell transplant patient receiving liposomal amphotericin B and caspofungin for suspected aspergillosis Infection 33 2005 397 400
55. J Pavie C Lacroix DG Hermoso Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis J Clin Microbiol 43 2005 4902 4904
56. C Charlier E Hart A Lefort Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 57 2006 384 410
57. AJ Ullmann JH Lipton DH Vesole Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease N Engl J Med 356 2007 335 347
58. OA Cornely J Maertens DJ Winston Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia N Engl J Med 356 2007 348 359
59. C Cordonnier M Mohty C Faucher Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study Int J Antimicrob Agents 31 2008 135 141
60. J El-Cheikh C Faucher S Furst High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation Bone Marrow Transplant 39 2007 301 306
61. E Roman I Osunkwo O Militano E Cooney C van de Ven MS Cairo Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation Pediatr Blood Cancer 50 2008 325 328
62. PL Olliaro PJ Guerin S Gerstl AA Haaskjold JA Rottingen S Sundar Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980–2004 Lancet Infect Dis 5 2005 763 774
63. S Sundar G Agrawal M Rai MK Makharia HW Murray Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial BMJ 323 2001 419 422
64. RN Davidson L di Martino L Gradoni Short-course treatment of visceral leishmaniasis with liposomal amphotericin B (AmBisome) Clin Infect Dis 22 1996 938 943
65. S Sundar TK Jha CP Thakur M Mishra VP Singh R Buffels Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study Clin Infect Dis 37 2003 800 804
66. F Laguna S Videla ME Jimenez-Mejias Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study J Antimicrob Chemother 52 2003 464 468
67. CM van der Horst MS Saag GA Cloud Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group N Engl J Med 337 1997 15 21
68. MM Roden TE Zaoutis WL Buchanan Epidemiology and outcome of zygomycosis: a review of 929 reported cases Clin Infect Dis 41 2005 634 653